Innovative Therapies Better Health

Innovative Therapies Better Health

Innovative Therapies Better HealthInnovative Therapies Better HealthInnovative Therapies Better Health

News and Press Release


YiSheng BioPharmaand Tavotek BioTherapeutics Announce Strategic Research Alliance Evaluating Investigational Combination of YS-ON-001 and Tavo-201/203 for Cancer Use

January 6, 2020 at 7:00 AM EST



Our Mission


Become a global leader in innovative molecular-targeted Biologics to improve patient quality of life

Our Passion


We are passionate about our global organization recognized for impact in drug discovery and development. We embrace 

•Talented people with motivation and collaboration skills 

•Science driven personnel •Sustainability and diversity 

Platform and Technology


 •TavoSelect Phage Library Platform  

 •TBE-Targeted Biologics Engineering Platform 

 •TIM-Tavo Immune Modulator Platform 

 •MIP-Multicyclic Intracellular Peptide Platform 

About Tavotek

Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. 

Tavotek has a rich pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases. 

Company management and advisors are veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for Biologics:

· TBE – monoclonal and multispecific antibodies against unique targets;

· TIM – novel synthetic biologic design for auto-immune diseases and chronic viral infections

· MIP – unique multi-cyclic peptides with great potency targeting intra-cellular protein-protein interactions

Tavotek has a rich and diverse pipeline across multiple therapeutic areas. It has the global angle with operations in Asia and North America. 

Tavotek’s development strategy includes organic growth, biopharma collaboration, and potential clinical stage asset licensing.